ANTX AN2 THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, AN2 THERAPEUTICS INC reported revenue of n/a, net income of −$8.19M and diluted EPS of −$0.18; for the fiscal year ended December 2025 revenue was n/a.
ANTX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$38.1M, net income −$35.2M (margin n/a), EPS −$1.16
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$56.8M, net income −$51.3M (margin n/a), EPS −$1.72
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$69.6M, net income −$64.7M (margin n/a), EPS −$2.74
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$42.3M, net income −$41.0M (margin n/a), EPS −$2.79
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$21.6M, net income −$21.5M (margin n/a), EPS −$10.64
ANTX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$8.19M, EPS −$0.18
- Quarter ended Mar 31, 2026: revenue n/a, net income −$10.0M, EPS −$0.29
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$8.71M, EPS −$0.29
- Quarter ended Sep 30, 2025: revenue n/a, net income −$9.35M, EPS −$0.31
- Quarter ended Jun 30, 2025: revenue n/a, net income −$6.46M, EPS −$0.21
- Quarter ended Mar 31, 2025: revenue n/a, net income −$10.6M, EPS −$0.35
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$7.52M, EPS −$0.25
- Quarter ended Sep 30, 2024: revenue n/a, net income −$12.7M, EPS −$0.43
- Quarter ended Jun 30, 2024: revenue n/a, net income −$14.4M, EPS −$0.48
- Quarter ended Mar 31, 2024: revenue n/a, net income −$16.6M, EPS −$0.56
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$16.9M, EPS −$0.49
- Quarter ended Sep 30, 2023: revenue n/a, net income −$16.7M, EPS −$0.65
- Quarter ended Jun 30, 2023: revenue n/a, net income −$15.8M, EPS −$0.81
- Quarter ended Mar 31, 2023: revenue n/a, net income −$15.3M, EPS −$0.79
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$11.8M, EPS $1.31
- Quarter ended Sep 30, 2022: revenue n/a, net income −$11.3M, EPS −$0.59
- Quarter ended Jun 30, 2022: revenue n/a, net income −$10.1M, EPS −$0.53
- Quarter ended Mar 31, 2022: revenue n/a, net income −$7.66M, EPS −$2.98
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$7.55M, EPS −$3.60
- Quarter ended Sep 30, 2021: revenue n/a, net income −$6.94M, EPS −$3.35
ANTX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$29.8M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$49.3M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$53.3M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$33.5M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$20.5M, share buybacks n/a
ANTX balance sheet
- Jun 30, 2026: cash $44.3M, total assets $81.7M, total liabilities $5.76M, shareholders' equity $75.9M
- Mar 31, 2026: cash $53.5M, total assets $87.5M, total liabilities $5.73M, shareholders' equity $81.8M
- Dec 31, 2025: cash $19.9M, total assets $62.0M, total liabilities $8.89M, shareholders' equity $53.1M
- Sep 30, 2025: cash $18.0M, total assets $67.2M, total liabilities $6.86M, shareholders' equity $60.4M
- Jun 30, 2025: cash $18.2M, total assets $75.8M, total liabilities $6.98M, shareholders' equity $68.8M
- Mar 31, 2025: cash $20.0M, total assets $81.3M, total liabilities $8.01M, shareholders' equity $73.3M
- Dec 31, 2024: cash $21.4M, total assets $92.1M, total liabilities $10.2M, shareholders' equity $81.8M
- Sep 30, 2024: cash $33.5M, total assets $97.7M, total liabilities $10.0M, shareholders' equity $87.7M
Is ANTX profitable?
No. AN2 THERAPEUTICS INC lost $36.3M over the last four quarters.
What is ANTX's EPS?
Diluted earnings per share over the last four quarters were −$1.07; −$0.18 in the latest quarter.